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Abstract: UDP-glucose dehydrogenase (UGDH) catalyzes two oxidations of 
UDP-glucose to yield UDP-glucuronic acid. Pathological overproduction of 
extracellular matrix components may be linked to the availability of UDP-
glucuronic acid; therefore UGDH is an intriguing therapeutic target. Specifi c 
inhibition of human UGDH requires detailed knowledge of its catalytic mech-
anism, which has not been characterized. In this report, we have cloned, ex-
pressed, and affi nity-purifi ed the human enzyme and determined its steady 
state kinetic parameters. The human enzyme is active as a hexamer with val-
ues for Km and
 Vmax that agree well with those reported for a bovine homolog.
 
We used crystal coordinates for Streptococcus pyogenes UGDH in complex 
with NAD+ cofactor and UDP-glucose substrate to generate a model of the 
enzyme active site. Based on this model, we selected Cys-276 and Lys-279 
as likely catalytic residues and converted them to serine and alanine, respec-
tively. Enzymatic activity of C276S and K279A point mutants was not mea-
surable under normal assay conditions. Rate constants measured over sev-
eral hours demonstrated that K279A continued to turn over, although 250-fold 
more slowly than wild type enzyme. C276S, however, performed only a sin-
gle round of oxidation, indicating that it is essential for the second oxidation. 
This result is consistent with the postulated role of Cys-276 as a catalytic res-
idue and supports its position in the reaction mechanism for the human en-
zyme. Lys-279 is likely to have a role in positioning active site residues and in 
maintaining the hexameric quaternary structure. 
Abbreviations: UGDH, UDP-glucose dehydrogenase; FPLC, fast protein 
liquid chromatography
Introduction 
UDP-glucose dehydrogenase (UGDH) catalyzes the conversion 
of UDP-glucose to UDP-glucuronic acid, an essential precursor for 
synthesis of extracellular matrix polysaccharides in numerous di-
verse species, including humans. The normal cellular functions of 
UGDH have been studied extensively in various organisms by tar-
geted gene disruptions, and these studies demonstrate its importance 
in developmental processes. In Drosophila melanogaster, the en-
zyme is encoded by the sugarless gene and is required for heparan 
sulfate modifi cation of proteins that control wing formation (1). In 
Caenorhabditis elegans, UGDH fuels the production of glycosami-
noglycans essential for vulval morphogenesis and embryonic devel-
opment (2). In zebrafi sh, the enzyme is critical for normal cardiac de-
velopment (3), and the phenotype of targeted disruption is extremely 
similar to the murine HAS2 null (4); both phenotypes are lethal. Hu-
man and mouse HAS2 proteins are 97% identical and are responsi-
ble for production of hyaluronan at specifi c developmental stages (5). 
Because UGDH provides the requisite UDP-glucuronic acid precur-
sor for hyaluronan synthesis, it is not surprising that UGDH null and 
HAS2 null would exhibit similar developmental impairments. 
Hyaluronan is an extracellular matrix component that is involved 
directly in promoting normal cellular growth and migration, but its 
elevated production has been extensively implicated in the progres-
sion of epithelial cancers such as breast (6), colon (7), and prostate 
(8). Such elevated synthesis of hyaluronan places increased demand 
on intracellular UDP-glucuronic acid concentrations, which also 
must be increased to compensate. Inhibition of hyaluronan synthesis 
recently has been shown to reduce tumor angiogenesis and thereby 
restrict in vivo growth of human prostate tumors (9). Restriction of 
precursor availability by inhibition of UGDH may regulate the pro-
duction of hyaluronan in tumors and therefore is a possible novel av-
enue for therapeutic intervention. Interestingly, UGDH was identifi ed 
in breast cancer cells as a gene product dramatically up-regulated in 
response to elevated androgen (10), so an androgen-secreting organ 
such as the prostate may have a mechanism for increased UGDH ex-
pression. Although a clone of human UGDH has been reported (11), 
kinetic properties and detailed mechanistic characterization of the pu-
rifi ed enzyme (a necessary prelude to inhibitor design) are not avail-
able yet. 
Kinetic studies of the bovine (12–20), streptococcal (21–24), and 
plant (25, 26) enzymes have been reported. All forms of the enzyme 
are known to catalyze the same reaction. Two successive oxidations 
are performed by the enzyme to convert the 6’-hydroxyl of UDP-glu-
cose to a carboxylate concurrent with reduction of 2 mol of NAD+ 
to NADH. Early experiments to determine an enzyme mechanism in 
the bovine system preceded the availability of sequence information, 
so specifi c catalytic residues were not identifi ed. However, results of 
these studies led to the interesting mechanism proposed in Scheme 
1 in which we have numbered key residues identifi ed in our exper-
iments. According to analysis of the bovine enzyme, in the fi rst step 
the 6’-carbon of UDP-glucose is thought to be covalently attached in 
a Schiff base linkage with a lysine residue at the active site of the pro-
tein. There is evidence to suggest that this imine undergoes the fi rst 
oxidation step yielding an aldimine intermediate that is not released 
from the protein. The aldimine is hydrolyzed/attacked by an active 
site cysteine to yield a thiohemiacetal that has been detected in both 
bovine and streptococcal enzyme systems. This intermediate then is 
oxidized a second time to produce a thioester,  which is spontaneously 
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hydrolyzed to release UDP-glucuronic acid as a product. Hydro-
lysis of the thioester is thought to be rate-limiting overall. Notably, 
the streptococcal enzyme is believed to form a covalent intermedi-
ate specifi cally between the product of the fi rst oxidation and cyste-
ine 260 within the active site, which is required for the second ox-
idation. This residue is uniformly conserved across all species and 
corresponds to cysteine 276 in the human enzyme. 
In this report, we have cloned, expressed, and purifi ed recombi-
nant human UGDH. To our knowledge, this is the fi rst characteriza-
tion of the human enzyme as well as the fi rst mammalian UGDH to 
be purifi ed and characterized by site-directed mutagenesis. We have 
determined that the enzyme is active as a hexamer with some evi-
dence for assembly in a trimer of dimers as has been proposed for 
the bovine enzyme. Steady state kinetic constants were established 
and found to be comparable with previously published data in the bo-
vine system. In addition, we generated a structural model of human 
UGDH based on the published crystal coordinates for the streptococ-
cal homolog. Using this model and primary sequence alignments of 
known UGDH family members, we selected Cys-276 and Lys-279 as 
likely active site catalytic residues and converted them to serine and 
alanine, respectively. Enzymatic activity of C276S and K279A point 
mutants was not measurable under normal assay conditions. Rate 
constants were measured over several hours and demonstrated that 
K279A continued to turn over, although 250-fold more slowly than 
wild type enzyme. C276S, however, performed only a single round 
of oxidation indicating that it is essential for the second oxidation. 
This result is consistent with the postulated role of Cys-276 as a cat-
alytic residue as shown in Scheme 1 and supports its position in the 
reaction mechanism for the human enzyme. Lys-279 appears to func-
tion structurally in preserving both the active site architecture and 
quaternary structure of the enzyme. 
Experimental Procedures 
Construction of Expression Vectors for Wild Type UGDH and Point Mu-
tants—Reverse-transcribed poly(A)+ RNA isolated from human prostate tu-
mor cells was used as a template for PCR. Oligonucleotides were designed us-
ing the published sequence for human UGDH (Gen-Bank™ accession number 
AF061016) to incorporate an NheI restriction enzyme site immediately prior 
to the ATG start codon and a SalI site subsequent to the stop codon. The resul-
tant 1.5-kb PCR product was digested with the relevant enzymes and ligated 
into similarly digested pET28a, a prokaryotic expression vector incorporating 
a cleavable N-terminal His tag (Novagen). Point mutants were generated us-
ing the QuikChange site-directed mutagenesis kit (Stratagene) following the 
manufacturer’s protocol. Point mutant coding sequences were subcloned in 
pET28a. All subclones were sequenced by the Genomics Core at the Uni-
versity of Nebraska-Lincoln. 
Expression and Purifi cation of Wild Type and Mutant UGDH—The re-
combinant plasmids encoding N-terminal His6 fusions to UGDH
 and the point 
mutants C276S and K279A were used to transform Escherichia coli strain 
Rosetta(DE3)pLysS (Novagen). Cultures were grown to an A600 of 0.6-0.8 in 
2xYT media containing 34 mg/liter chloramphenicol and 30 mg/liter kanamy-
cin at 30 °C and then were induced for 4 h by the addition of isopropyl-1-thio-
β-D-galactopyranoside to a fi nal concentration of 0.5 mM. The cells were har-
vested by centrifugation and resuspended in 50 mM sodium phosphate buffer, 
pH 8.0, containing 0.3M NaCl and 10 mM imidazole. Cells were lysed by 
sonication and centrifuged for 15 min at 15,000 × g. All three recombinant 
proteins were found to be expressed in the soluble fraction. The supernatant 
was treated with 0.35% (v/v) polyethyleneimine at 4 °C for 30 min and centri-
fuged for 15 min at 15,000 × g to separate precipitated nucleic acids from the 
protein-containing soluble fraction. The enzyme then was purifi ed by affi nity 
chromatography using a nickel-chelating column (Novagen) according to the 
manufacturer’s protocol. Typical yields were 20-40 mg of purifi ed protein per 
liter of bacterial culture. All preparations were >95% pure based upon SDS-
PAGE (see Figure 1). The purifi ed protein was dialyzed against 20 mM Tris-
HCl, pH 7.4, and 1 mM dithiothreitol. By comparing uncleaved and thrombin-
cleaved protein in the activity assay described below, we investigated whether 
the N-terminal His tag affected wild type enzyme activity. The His tag was 
cleaved by incubating the protein with 1 unit/mg thrombin (Novagen) for 1 6 
h at 4 °C followed by dialysis against 20 mM Tris-HCl, pH 7.4, and 1 mM di-
thiothreitol. Cleavage of the tag was verifi ed by SDS-PAGE. Cleaved and un-
cleaved proteins were found to have identical enzymatic activity. Protein stor-
age conditions also were tested, and the protein, although stable at 4 °C for up 
to 48 h, was only stable long-term at –80 °C following fl ash freezing in a dry 
ice/acetone bath. Subsequent characterizations were performed exclusively, 
therefore, on aliquots of uncleaved protein stored in this fashion. 
Enzymatic Activity Measurement and Kinetic Characterizations—En-
zymatic activity of the wild type enzyme was determined by monitoring the 
change in absorbance at 340 nm that accompanies the reduction of NAD+ to 
NADH. For standard screening of enzymatic activity, the assay was performed 
for 30 s at room temperature in 0.1 M Tris-HCl buffer, pH 7.4, containing 1 
mM UDP-glucose (Fluka) and 10 mM NAD+ (Sigma). The Km and Vmax for 
UDP-glucose and NAD+ were determined independently using standard assay 
conditions. Constants for UDP-glucose as substrate were measured by hold-
ing NAD+ constant and varying [UDP-glucose] from 0 to 200 μM. Similarly, 
NAD+ kinetic measurements were made by holding UDP-glucose constant and 
varying NAD+ from 0 to 2 mM. Triplicate values were obtained for each mea-
surement, and data were plotted with Prism software (GraphPad). Km and Vmax 
were calculated by fi tting the data to the Michaelis-Menten equation and as-
suming a single binding site each for substrate and cofactor. 
Kinetic measurements for the two point mutants initially were made un-
der standard assay conditions, and activity was found to be negligible at the 
30-s time point. To determine whether residual enzymatic activity remained 
in these mutants, assays were set up with saturating cofactor and substrate, 
and an absorbance scan from 290 to 400 nm was collected every 5 min for 4 
h. The resulting A340 values then were replotted over the time course
 of the as-
say and analyzed in Prism by fi tting to a curve with a one-and two-phase ex-
ponential rate for C276S and K279A, respectively, to model the fi rst and sec-
ond oxidations of NAD+. 
Determination of Cofactor Binding Constants—To quantify cofactor 
binding independently of enzyme activity, intrinsic tryptophan fl uorescence 
was measured. The wild type protein was scanned to determine the wave-
length that gave maximum excitation (290 nm, data not shown); excitation 
at this value then was used to scan for maximum emission (335 nm). Each of 
the point mutants was scanned to verify equivalent excitation and emission 
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maxima. Intrinsic tryptophan fl uorescence was monitored using these excita-
tion and emission values in the presence of increasing NAD+ from 0 to 1.5 
mM. Kd values were obtained for each enzyme
 by fi tting corrected fl uores-
cence quenching to a curve with a single exponential decay (Prism). 
Molecular Mass Determination—The functional molecular mass of the 
active UGDH enzyme complex was determined by gel fi ltration chromatogra-
phy. Purifi ed recombinant UGDH wild type and point mutants were individ-
ually loaded on a Superdex 200 HR 10/30 column (Amersham Biosciences) 
and separated by FPLC in 50 mM NaPO4, pH 7.0, containing 150 mM NaCl, 
at a fl ow rate of 0.25 ml/min. Size determination was made by comparison 
with molecular weight standards (Amersham Biosciences) chromatographed 
under the same conditions. The molecular mass standards used (see inset plot 
of Figure 3) were as follows: thyroglobulin, 699 kDa; ferritin, 416 kDa; cata-
lase, 219 kDa; aldolase, 176 kDa; albumin, 67 kDa; ovalbumin, 47 kDa; chy-
motrypsinogen A, 20 kDa; RNase A, 15 kDa. Resolution was suffi cient to 
calculate molecular masses unambiguously in multiples of 57 kDa (the calcu-
lated molecular mass of monomeric His-tagged UGDH). 
Homology Modeling and Portrayal of Active Site Residues—Human 
UGDH is 23% identical to the Streptococcus pyogenes enzyme for which a 
crystal structure has been published. We modeled human UGDH using 3D-
PSSM (27), which superimposed the human amino acid sequence onto the 
Protein Data Bank coordinates for S. pyogenes UGDH (Protein Data Bank 
code 1DLI). A ribbon rendering of the model was made with Chimera (28). 
The active site was centered upon, and the model, in conjunction with se-
quence conservation, was used to select appropriate putative catalytic resi-
dues, which are depicted in Figure 4. 
Results 
Protein Expression and Purifi cation—Although the cDNA for 
human UGDH was expressed previously in eukaryotic cells and the 
functionality implied by its nomenclature verifi ed, no kinetic data 
were reported for the enzyme. Our goal was to measure steady state 
kinetic constants for wild type human UGDH, determine the subunit 
structure of the active enzyme complex, identify key active site res-
idues, and assess the role of each in the enzyme mechanism. To fa-
cilitate these characterizations, wild type UGDH and specifi c point 
mutants each were subcloned in a bacterial expression vector that en-
coded an N-terminal 6-histidine fusion for affi nity purifi cation. The 
resultant constructs expressed abundant soluble recombinant UGDH 
in E. coli, and each enzyme form was purifi ed to homogeneity by 
nickel affi nity chromatography (Figure 1). To verify that the N-ter-
minal histidine tag did not affect the structure or function of wild 
type UGDH or its mutants, the histidine tag was removed by throm-
bin cleavage, and the resulting protein was compared with uncleaved 
protein. Because cleaved and uncleaved proteins exhibited identical 
levels of enzyme activity (data not shown), uncleaved protein was 
used for subsequent characterizations. 
Kinetic Characterization of UGDH—UGDH catalyzes conver-
sion of a UDP-glucose substrate to a UDP-glucuronic acid product, 
concomitantly reducing two molecules of NAD+ to NADH. The en-
zymatic activity of wild type UGDH was characterized by steady 
state kinetic analysis. To obtain kinetic constants (Km and Vmax)
 for 
substrate and cofactor, we measured the steady state level of NADH 
by its absorbance at 340 nm. Measurements to determine the depen-
dence of the reaction on cofactor concentration were conducted using 
purifi ed UGDH incubated with increasing concentrations of NAD+ in 
the presence of saturating UDP-glucose substrate (Figure 2A). Simi-
larly, dependence of reaction kinetics on substrate was measured by 
increasing UDP-glucose concentration in the presence of saturating 
NAD+ (Figure 2B). Saturation kinetics were observed for both con-
ditions. Data were fi tted to the Michaelis-Menten equation to obtain 
Km and Vmax for the reaction catalyzed by
 the wild type enzyme (Ta-
ble I). Both sets of conditions yielded a similar Vmax of ≈120 nmol of 
NAD+/min/mg of enzyme. The Km
 for UDP-glucose was 11.2 μM, 
and the Km for NAD
+ was 355 μM. 
Characterization of UGDH Oligomeric State—Previous stud-
ies with S. pyogenes UGDH indicate that the enzyme is a dimer, but 
the bovine enzyme is considered to be hexameric. To determine the
Figure 1. Purity of wild type and mutant UGDH. Recombinant His-tagged 
human UGDH and specifi ed point mutants were overexpressed in E. coli and 
purifi ed to homogeneity from the soluble extract in a single nickel affi nity 
chromatography step. The purity of wild type UGDH (lane 1), C276S mutant 
(lane 2), and K279A mutant (lane 3) proteins was evaluated by SDS-PAGE 
followed by staining with GelCode Blue (Pierce). Proteins were judged to be 
>95% pure.
Figure 2.  Wild type UGDH demonstrates saturable kinetics for NAD+ 
(A) and UDP-glucose (B). Steady state enzyme activity was measured as 
conversion of NAD+ to NADH detected by absorbance at 340 nm. Purifi ed 
human UGDH (0.5 mg/ml in 0.1 M Tris-HCl, pH 7.4) was incubated for 1 
min with increasing concentrations of NAD+ (0-2 mM) in the presence of sat-
urating substrate (A, UDP-glucose, 2 mM) or with increasing concentrations 
of UDP-glucose in the presence of saturating cofactor (B, NAD+, 2 mM).
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oligomeric state of human UGDH, we performed size exclusion anal-
ysis by FPLC (Figure 3). Consistent with data for the bovine ortho-
log, human UGDH predominantly is observed as a hexamer eluting 
from the gel fi ltration column at a molecular mass corresponding to 
six times the single subunit mass (peak I). Signifi cant dimeric (II) 
and monomeric (III) species also are present, indicating some sub-
unit dissociation. This elution profi le was observed repeatedly over 
several different preparations of the enzyme with relative species ra-
tios conserved so the distribution of subunit structures appears to be 
an innate property of the enzyme. The inset panel shows molecu-
lar weight determination for the peaks on the basis of size exclusion 
standards. The functional enzyme was analyzed independently by dy-
namic light scattering (data not shown), which estimated its molecu-
lar mass at 345 kDa (hydrodynamic radius of 7.2 nm) consistent with 
a hexameric assembly of the 57-kDa monomers. 
Determination of UGDH Cofactor Binding Affi nity—To charac-
terize the initial binding of NAD+ cofactor to UGDH independently 
of its apparent binding during 2-fold oxidation in turnover, we moni-
tored the intrinsic tryptophan fl uorescence of UGDH. We determined 
that fl uorescence emission of the protein at 335 nm was quenched 
by the incremental addition of NAD+ (data not shown). Tryptophan 
quenching was plotted as a function of NAD+ concentration and fi t-
ted to an exponential decay assuming a single binding site (Prism). 
The resulting dissociation constant was 118 ± 3.3 μM (Table II). This 
value is comparable in order of magnitude to the Km for NAD
+ deter-
mined by catalytic turnover. 
Homology Modeling of UGDH—The structure for human UGDH 
has not been solved yet, but the human enzyme is 23% identical to its 
ortholog in S. pyogenes for which a structure was recently published. 
Using the coordinates of the bacterial enzyme complexed with cofac-
tor and substrate, we modeled the human enzyme as a ternary com-
plex with NAD+ cofactor and UDP-glucose substrate and inspected 
the architecture of the active site (Figure 4). The degree of structural 
similarity was suffi cient to identify specifi c residues in the human en-
zyme likely to participate in catalysis. Cys-260 of the streptococcal 
UGDH was mutagenized previously and found to reduce enzyme ac-
tivity. Based on the homology model of human UGDH and previ-
ously published studies of the bacterial enzyme, we identifi ed spe-
cifi c residues within the active site that were likely to be important 
for catalytic activity. We generated point mutations at residues Cys-
276 (the human analog of Cys-260) and Lys-279 to investigate their 
individual contributions to the enzyme mechanism. Figure 4 illus-
trates the position of these two residues in the active site of the hu-
man UGDH model relative to NAD+ and UDP-glucose. Also shown 
are side chains of residues Lys-220 and Asp-280 (see “Discussion”). 
Kinetic Characterization of UGDH Point Mutants—Catalytic ac-
tivity of UGDH point mutants C276S and K279A initially was mea-
sured under standard reaction conditions and found to be negligible. 
For C276S, this observation is consistent with results of the analo-
gous C260S streptococcal point mutant, which lacked activity to an 
unquantifi ed degree. To evaluate the role of each residue in cataly-
sis and determine the extent of impaired catalytic function, we per-
formed a time course over 4 h, measuring enzyme activity every 5 
min by absorbance wavelength scans from 290 to 400 nm. Conver-
sion of NAD+ to NADH by C276S (Figure 5A) was found to saturate 
at a concentration equimolar to that of added protein, suggesting that 
a single round of oxidation can occur in the absence of this cysteine 
but that the cysteine is essential for the second oxidation. In contrast, 
cofactor reduction was not saturable in the reaction catalyzed by the 
K279A mutant (Figure 5B), demonstrating its continued capacity for 
multiple turnover. 
Absorbance values at 340 nm were replotted as a function of as-
say time to determine kinetic constants for the reaction (Figure 5C). 
As mentioned above, values for C276S were observed to plateau at 
an A340 of ≈0.17. This absorbance value corresponds to a 1:1
 molar 
ratio of NADH produced relative to added protein. Under identical 
conditions, K279A continued to turn over without reaching an end 
point. 
Saturable C276S kinetic data were fi tted to an equation with a 
single rate for catalysis of ≈2.7 nmol of NAD+/min/mg of enzyme 
(Table III). This value is ~50-fold diminished from the overall rate of 
NAD+ turnover by wild type enzyme. Cys-276 therefore is not only 
essential for the second round of oxidation; it is also involved in ef-
fi cient execution of the fi rst round. Data replotted for K279A, which 
did not achieve saturation in the time course of the assay, revealed 
two rate constants. The fi rst, k1, was comparable with the rate con-
stant for C276S (≈2.5 nmol/min/mg), but was followed by a much 
slower rate, k2, of
 ≈0.4 nmol/min/mg. Hence, although not directly 
required for either oxidation, Lys-279 appears to have a global role in 
the catalytic function. 
Cofactor Binding by Wild Type and Mutant UGDH—To verify 
that observed differences in enzyme activity among wild type and 
point mutants of UGDH were not attributable to a loss of cofactor 
binding, we compared intrinsic tryptophan quenching in the presence 
of increasing concentrations of NAD+. Fluorescence emission was 
fi tted to a saturation curve assuming a single binding site. Resultant 
dissociation constants (Table II) demonstrate comparable cofactor af-
fi nities among wild type and mutant UGDH (118, 127, and 103 μM 
for wild type, C276S, and K279A, respectively), suggesting that the 
folded structures of the mutant proteins were unaffected by the re-
spective point mutation. Furthermore, loss of enzymatic activity was 
not the result of a change in binding of NAD+ by either mutant de-
spite the suggestive hydrogen bonding proximities illustrated by Fig-
ure 4 that might implicate Lys-279 in cofactor binding. 
Subunit Association of Mutant UGDH—Because altered cata-
lytic activity of the mutants also could result from changes in qua-
ternary structure, the oligomeric state of the mutant enzymes was ex-
amined for perturbations by size exclusion FPLC. Whereas C276S 
retained a predominantly hexameric structure with a minor dimeric 
peak as compared by overlay of its elution profi le on that of the wild 
type enzyme (Figure 6A), K279A is found almost exclusively as a di-
mer (Figure 6B). This observation is consistent with the UGDH qua-
ternary structure adopting a “trimer of dimers” arrangement within 
the hexameric protein. Although the homology model of UGDH does 
not predict a surface exposed location for Lys-279, it appears to be 
required for maintenance of the trimer interfaces that must occur in-
dependently of dimerization. 
Discussion 
UGDH is expressed by most species from bacteria to humans. 
In plants and bacteria, its role is in the maintenance of structural in-
tegrity. In animals, its functional signifi cance is developmental, and 
its dysregulation is linked indirectly to several pathologies, including 
cancer progression. Specifi c targeted inhibition of this enzyme may 
offer a therapeutic avenue but requires a detailed understanding of its
Table I
Steady state kinetic constants for wild type UGDH
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mechanism. To date, most mechanistic studies have focused on the 
bovine or bacterial forms of the enzyme. In the study we have pre-
sented here, human UGDH was cloned, expressed, and purifi ed to 
homogeneity. We report the fi rst characterization of its mechanistic 
features. Kinetic properties of the hexameric enzyme are comparable 
with those reported previously for UGDH orthologs. Specifi c point 
mutants were generated based on homology modeling of the enzyme 
and used to dissect the components of the enzyme reaction sequence. 
Cys-276 is required for the second but not the fi rst of the two succes-
sive oxidations. Lys-279 is not an absolute requirement for activity, 
but mutation of this residue impairs catalysis and disrupts the quater-
nary structure of the protein. Its role probably is to position the active 
site cysteine for maximally effi cient catalysis, but it may also be an 
important contact at the trimeric interface. 
Human UGDH is closely related to the enzyme characterized 
from bovine liver but is only 23% identical to the S. pyogenes en-
zyme, both of which catalyze the same 2-fold oxidation of UDP-glu-
cose to UDP-glucuronic acid, apparently by similar mechanisms. Not 
surprisingly, the kinetic activity and quaternary structure of the wild 
type human protein are very similar to the bovine; the kinetic con-
stants we have measured are within 2-fold of those reported for the 
bovine enzyme, which also functions as a hexamer (16). The S. pyo-
genes enzyme, in contrast, is dimeric and has slightly lower binding 
constants for substrate and cofactor relative to both mammalian pro-
teins (23). It is not clear what role subunit associations may play in 
enzyme function. Both substrate binding assays and chemical mod-
ifi cations of the active site cysteines in the bovine enzyme suggest 
that there is half-site reactivity among the subunits in the trimer of di-
mers that is induced through subunit communication following the 
fi rst binding event (17, 20). This phenomenon may provide a regula-
tory mode for human and bovine UGDH. Although it is possible that 
the reduced activity of our K279A mutant is attributable to its altered 
subunit structure, we have additionally generated a point mutant, 
K339A, that also is dimeric but exhibits activity comparable with 
that of wild type (data not shown). Lys-279 is shown by the homol-
ogy model to be located in a solvent-exposed stretch of helix adjacent 
to the dimerization interface. Evolutionarily speaking, the hypothe-
sis has been put forth that the bacterial enzyme preceded the animal 
forms (11). The dimer interface then most likely would be conserved 
among species, and the contacts between dimers would be elsewhere. 
The quaternary structures of our lysine mutants are consistent with 
conserved localization of the dimer interface and predict that interdi-
mer association occurs through contacts maintained, at least in part, 
by the solvent-exposed helix containing Lys-279. 
Site-directed mutagenesis is a powerful tool with which to func-
tionally dissect the roles of residues within an enzyme active site. To 
Figure 4.  Active site model of the UGDH ternary complex. The human 
UGDH primary sequence was superimposed on the published crystal struc-
ture coordinates for the S. pyogenes enzyme (Protein Data Bank code 1DLI). 
A model was generated using 3D-PSSM and was represented in Chimera as 
a ribbon diagram. The model depicts the human enzyme in complex with 
NAD+ cofactor and UDP-glucose substrate. Side chains of specifi c active site 
residues discussed in the text are shown. The network of hydrogen bonding 
between protein active site residues and the cofactor and substrate is illus-
trated by dotted lines (see “Discussion”). The coloring scheme is as follows: 
the overall helical ribbon is blue and the loops are yellow; within the active 
site, carbon atoms of the protein are gray, carbons in the cofactor and sub-
strate are green, nitrogen is blue, oxygen is red, sulfur is yellow, and phos-
phorus is pink.
Figure 3.  Wild type UGDH is active as a hexamer. 
Purifi ed human UGDH was fractionated by gel fi ltra-
tion FPLC on a Superdex 200 HR 10/30 resin. One 
major and two minor peaks were detected as dis-
cussed in the text. Size determination was made by 
comparison with molecular weight standards frac-
tionated under identical conditions. Average reten-
tion time in the column was plotted versus the log of 
the molecular weight for each standard (inset). Stan-
dards used were as follows: thyroglobulin, 699 kDa; 
ferritin, 416 kDa; catalase, 219 kDa; aldolase, 176 
kDa; albumin, 67 kDa; ovalbumin, 47 kDa; chymo-
trypsinogen A, 20 kDa; RNase A, 15 kDa.
Table II
NAD+ binding constants for wild type and mutant UGDH
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date, only one such study has been done; cysteine 260 of S. pyogenes 
UGDH was converted to a serine, and the mutant lost activity but 
no quantitative data were published (24). Active site residues in the 
bovine enzyme have been identifi ed by chemical modifi cations only. 
We sought to acquire mechanistic details for the human enzyme by 
a combination of site-directed mutagenesis, activity measurements, 
and homology modeling. Although only 23% identical to bacterial 
UGDH, the sequence of the human enzyme mapped well onto the 
crystal coordinates determined for the bacterial enzyme. By model-
ing the protein in this fashion, we were able to generate an image 
of the putative interactions within the active site of a ternary com-
plex composed of human UGDH, NAD+ cofactor, and UDP-glucose 
substrate (Figure 4). Inspection of this model, combined with iden-
tifi cation of conserved residues in a primary sequence alignment of 
UGDH across diverse species and consideration of published data for 
the bovine and bacterial enzymes, directed us toward the selection 
of two key conserved amino acid residues likely to have a role in the 
catalytic mechanism: Cys-276 and Lys-279. 
The fi gure illustrates a network of hydrogen bonding interactions 
within the active site that may serve to stabilize the ternary complex 
and facilitate catalysis. Lys-279 appears to bind the 3’-hydroxyl of 
the NAD+ ribose (though mutation of that residue had no effect on 
our NAD+ binding data) and forms an electrostatic interaction with 
Asp-280. Asp-280, in turn, positions a water molecule at the active 
site, thereby indirectly linking to NAD+, the 6’-OH of the substrate, 
and Cys-276. This water molecule may be a structural edifi ce or a 
component of the reaction mechanism. It has been suggested that the 
water molecule would serve as a general base for proton abstraction 
during the fi rst oxidation step in the bacterial reaction scheme (23). 
Figure. 5.  Kinetic comparison of UGDH point mutants. Purifi ed recom-
binant UGDH point mutant enzyme activity was assayed as conversion of 
NAD+ to NADH detected by absorbance scans from 290 to 400 nm. Standard 
conditions used for wild type enzyme produced no activity from the mutant 
enzymes, so a time course was performed. A, C276S scans at 5-min intervals 
to 4 h. B, K279A scans at similar time points. C, absorbance at 340 nm was 
replotted over the time course of the assay to compare NADH appearance for 
C276S (solid line) and K279A (dotted line).
Table III
Rate constants for wild type and mutant UGDH
Figure 6.  Size determination of UGDH point mutant structures. Molec-
ular mass of the functional point mutant enzyme complexes was measured 
by FPLC as described under “Experimental Procedures” and in the legend 
to Figure 3. A, C276S superimposes on the wild type trace and is likely hex-
americ. B, K279A superimposes on the wild type dimer, indicating that this 
mutant is functioning predominantly as a dimer in kinetic assays.
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Its central location at the active site then would be important to pre-
serve and would depend on interactions donated by Lys-279 and Cys-
276, but our data do not address this directly. The cysteine thiol thus 
positioned is within hydrogen bonding distance of the 6’-hydroxyl of 
UDP-glucose and is located appropriately for catalysis. 
The mechanism proposed for bacterial UGDH involves the pro-
duction of UDP-hexodialdose as an intermediate (21). Catalysis then 
is postulated to proceed via formation of a thiohemiacetal between 
Cys-276 and this intermediate, which is oxidized to a thioester before 
hydrolysis to yield the fi nal carboxylate product. Our data demon-
strate that Cys-276 is capable of a single NAD+ reduction, which is 
consistent with this hypothesis. However, the hexodialdose interme-
diate never has been isolated either from the bacterial or the bovine 
reaction system. Instead, investigators of the bovine system postu-
lated a reaction intermediate that was covalently linked to the enzyme 
and not released between oxidations (14). Ordman and Kirkwood 
(14) hypothesized a Schiff base intermediate that would be linked 
via an active site lysine. To demonstrate this and identify the enzyme 
residue linkage, these authors derivatized the putative active lysine 
with [14C]formaldehyde and reduced with NaBH4, thereby placing a 
mechanism-dependent label at the active site. These studies clearly 
suggest that the enzyme fi rst forms a Schiff base linkage with the 6’-
carbon of UDP-glucose, allowing the C-6’-hydroxyl subsequently to 
undergo the fi rst oxidation, as we have depicted in Scheme 1. Our 
data using C276S also are consistent with this scheme. Interestingly, 
although Lys-279 appeared to be important for maximally effi cient 
catalysis, its role is probably indirect: to constrain the position of an 
essential catalytic residue or the active site water. Accordingly, we 
have mutagenized an additional lysine, K220A, which entirely lacks 
enzymatic activity, implying that Lys-220 is an essential catalyst for 
the fi rst oxidation of UDP-glucose and highlighting it as a candidate 
for the Schiff base intermediate. (B. J. Sommer, J. J. Barycki, and M. 
A. Simpson, manuscript in preparation.)
The collective summary of the studies described suggests to 
us the reaction mechanism as outlined in Scheme 1 with key resi-
dues we have identifi ed illustrated in their respective roles. The reac-
tion sequence is initiated by the binding of UDP-glucose, followed 
by NAD+. Lys-220 forms a covalent linkage to the C-6’ of UDP-glu-
cose, the hydroxyl is lost as water, and the secondary amine is oxi-
dized to a Schiff base between C-6’ and Lys-220, releasing NADH. 
The thiol of Cys-276 simultaneously attacks C-6’ as water hydro-
lyzes the Schiff base, forming a thiohemiacetal that is oxidized by re-
duction of a second NAD+ to the thioester. Hydrolysis of the thioes-
ter releases the fi nal UDP-glucuronic acid product. The mechanism 
suggests that specifi c inhibitors may be most effective at the level of 
Schiff base or thiohemiacetal formation because these would exploit 
the retention of covalent intermediates by the enzyme and be mecha-
nistic inhibitors. 
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